drugset / Trial / NCT06716619
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
Phase 1
Recruiting
32 enrolled
Guangzhou FineImmune Biotechnology Co., LTD.
Sun Yat-sen University · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase I clinical trial of the safety and tolerability of tumor-associated lymph node T cell injection in patients with advanced malignant solid tumors, including but not limited to melanoma, head and neck tumors, cervical cancer, and non-small cell lung cancer.
Timeline
- Start
- 2025-02-13
- Primary completion
- 2026-12-19
- Completion
- 2027-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Associated Lymph node T cell | Cell therapy | — | — |
| Background | Serplulimab | Monoclonal antibody | — | Intravenous |